GLP-1s not tied to more fragility fractures in two cohorts
Obesity cohort on the drugs had 30% lower fragility fracture risk across sites.
22 September 2026 · Healio
Clinic
Weight-loss shots
37 clippings on the rack, newest printed 22 September 2026.
Earlier cuttings
One in six teens on GLP-1s got a new nutrient diagnosis
Among about 2,000 ages 10–17 started 2017–2022, 17% were diagnosed within a year.
22 Sept · Gizmodo
CagriSema tops tirzepatide on weight in diabetes trial
Topline REIMAGINE 5: 12.4% vs 9.1% at 60 weeks on the efficacy estimand.
21 Sept · Healio
ASCO data show lower breast cancer incidence with GLP-1s
Women who used the drugs had 30% lower incidence than nonusers in presented work.
18 Sept · Healio
Lula says obesity pens should be free on the SUS
The remark came the same day the government announced a 15% Bolsa Família reajuste.
17 Sept · Folha de S.Paulo
Wegovy’s SELECT heart benefit held across frailty
A JAMA Cardiology post-hoc analysis of 17,604 SELECT patients stratified them with a 31-item frailty index.
17 Sept · Healio
Starter-dose GLP-1s still cut weight, far less than full strength
Low-dose tirzepatide averaged 5.5% body-weight loss over a year; low-dose semaglutide 2.2%.
17 Sept · Yahoo Finance
Rare Wernicke cases flagged in GLP-1 users
An Israeli review of FDA adverse-event reports and literature found 15 cases in 2023-2024.
15 Sept · The Independent
Review flags mixed NAION signal with GLP-1 drugs
Evidence on NAION with GLP-1 drugs is mixed, including a semaglutide odds ratio of 3.9 in 78 randomized trials.
14 Sept · Healio
GLP-1 activity linked to extra hair-loss risk in men
Men already genetically prone to male-pattern baldness faced an additional 7 percent hair-loss risk.
12 Sept · ScienceDaily
GLP-1 scripts in 8- to 11-year-olds jump 310-fold
Prevalent prescribing rose from 0.03 to 9.3 percent from 2019 to 2026.
11 Sept · Clinical Advisor
Fifth Circuit backs FDA end to GLP-1 shortage listing
Unpublished rulings leave compounders without the shortage exception for copies of Ozempic, Wegovy, Mounjaro and Zepbound.
10 Sept · Clark Hill
Pre-op GLP-1 did not change 1-year bariatric weight loss
Mean total body weight loss was 24% with preoperative GLP-1 versus 25% without it.
9 Sept · Healio
Kenya starts screening Mounjaro, not yet for sale
The Pharmacy and Poisons Board received Aspen Pharmacare’s registration file on May 7, 2026.
9 Sept · Business Daily
GLP-1-only care rose to 96.1% of treated youth
Surgery-only share fell from 11.6% to 3.7% among 204,148 people aged 13 to 25.
8 Sept · Healio
Weekly Wegovy cut BMI more than placebo in children 6 to 11
Topline STEP Young results cover 165 children treated for 68 weeks with diet and activity counseling.
8 Sept · Healio
Semaglutide tied to fewer asthma attacks in UK records
Observational analysis found nearly 40 per cent fewer asthma attacks among people starting the drug.
8 Sept · The Independent
Bermuda recalls three semaglutide injection products
Novo Nordisk Canada Inc lot LP1107, multiple Dr Reddy’s lots and Apotex lot 7000599A are named.
8 Sept · The Royal Gazette
Structure oral GLP-1 shows 16.2% loss without a plateau
The 180-mg aleniglipron dose reached that figure at 72 weeks in the company’s press release.
8 Sept · BioSpace
Semaglutide tied to fewer asthma attacks in UK records
Four parallel studies each covered 20,000 to 22,000 people starting GLP-1 treatment or sulfonylureas.
7 Sept · News-Medical
Zepbound plus Taltz held skin and weight gains at one year
PASI 100 plus at least 10% weight loss hit 30.6% on combination versus 4.4% on Taltz alone in TOGETHER-PsO.
1 Sept · Healio
Four obesity drugs show no extra respiratory harm versus placebo
Liraglutide, semaglutide, tirzepatide and naltrexone-bupropion had no higher respiratory adverse-event risk in a 122-study systematic review and meta-analysis.
31 Aug · Healio
Unapproved retatrutide sold via Belfast Facebook
Advertised prices ran £140 to £250 for a single pre-filled research pen labelled research purpose only.
29 Aug · The Irish News
Mouse hunger cells keep semaglutide weight loss going
Hunger cells help the newer GLP-1 drugs stick.
29 Aug · Earth.com
Canada GLP-1 retail sales reach about $2.4-billion in half year
Ozempic accounted for about $1.49-billion in retail pharmacies in the first half of 2026.
27 Aug · theglobeandmail.com
Fifth Circuit backs FDA on tirzepatide pens
On Aug. 27, 2026, the Fifth Circuit affirmed FDA’s removal of Mounjaro and Zepbound injections from the shortage list.
27 Aug · ca5.uscourts.gov
Zepbound tied to lower medical bills in adults over 55
By 12 months, estimated healthcare-cost differences reached up to $607 per patient per month versus untreated peers.
26 Aug · investor.lilly.com
Pipeline still favors weekly pens
Prime Therapeutics dated August 25, 2026 listed Novo Nordisk’s injectable fixed-dose combination of semaglutide and cagrilintide for weight loss with an FDA decision expected in December 2026.
25 Aug · primetherapeutics.com
Zepbound cash prices by weekly dose
In August 2026 typical cash prices for Zepbound ranged from about $300 per month for the 2.5 mg starter dose to roughly $691 per month for the 10–15 mg maintenance doses.
21 Aug · rx.com
Survodutide weekly shots cut weight in SYNCHRONIZE-1
At week 76, mean body-weight change was –13.0% on 6.0 mg survodutide versus –5.4% on placebo.
20 Aug · nejm.org
Weekly shots still lead the obesity list
On August 12, 2026 the Obesity Medicine Association listed injectable semaglutide and tirzepatide as the leading weekly options after the 2021 and 2023 approvals.
12 Aug · obesitymedicine.org
Lilly quarter driven by Mounjaro and Zepbound volume
Second-quarter 2026 revenue reached $23.0 billion, up 48%.
5 Aug · investor.lilly.com
Novo’s obesity shots still move the books
Novo’s Aug. 2026 Q2 deck put U.S. Wegovy weekly prescriptions near 575,000 as of July 17.
5 Aug · novonordisk.com
CVS puts Zepbound on the app
By early fourth quarter of 2026, eligible Zepbound and Foundayo patients will see transparent pricing, including cash-pay, in the CVS Health app for same-day pickup at 9,000 locations.
5 Aug · cvshealth.com
FDA flags unapproved GLP-1s and compounding limits
Retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition.
FDA
FDA flags unapproved GLP-1s for weight loss
Retatrutide and cagrilintide cannot be used in compounding under federal law.
FDA
Zepbound pens undercut Wegovy on milligram cost
Zepbound 15 mg pen cartons list at $699 a month through LillyDirect, or about $12 per milligram.
rx.com
Five clippings on Weight-loss shots every morning, and you're done. iPhone.